AbbVie announced the final analysis of the confirmatory Phase III MIRASOL trial evaluating the efficacy and safety of Elahere (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive… read more.
Eli Lilly announced results from the Phase III BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor in adult patients with chronic lymphocytic leukemia or… read more.
Pfizer Inc. announced positive topline results from the progression-free survival (PFS) analysis of the Phase III BREAKWATER study of Braftovi (encorafenib) in combination with cetuximab (Erbitux) and mFOLFOX6… read more.
Regeneron Pharmaceuticals, Inc. announced positive results from the Phase III C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically significant and… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Calquence…. read more.
NICE (UK): Selpercatinib is recommended as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults,… read more.
A largescale study has found huge variation between GP practices on whether they are likely to pick up prostate cancer using a blood test. The University of Exeter… read more.
GSK plc announced that the National Medical Products Administration (NMPA) of China has accepted for review a new drug application (NDA) for Blenrep (belantamab mafodotin) in combination with… read more.
A new paper in the Journal of Breast Imaging, published by Oxford University Press, indicates that breast cancer mortality rates have stopped declining in women older than age 74, and… read more.
The prognosis for pancreatic cancer (PC) patients is among the worst of all cancers. Globally, just 13% of patients who are diagnosed with PC survive for five years… read more.
Pfizer Inc. announced positive results from the Phase III BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with… read more.
Soligenix, Inc announced its lead investigators for the cutaneous T-cell lymphoma (CTCL) and psoriasis programs are presenting findings from recent supportive trials with HyBryte™ (synthetic hypericin) in the… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
